Defiance Daily Target 2X Long AMKR ETF (AMKL)
Leveraged ETFs that chase single volatile stocks amplify everything — upside and downside alike — but their daily reset mechanics can silently erode value when volatility spikes.
AMKL is a 2X leveraged exchange-traded fund that tracks Marker Therapeutics, a clinical-stage immunotherapy company trading under the ticker AMKR. The fund is sponsored by Defiance ETFs and is designed to amplify the daily returns of AMKR by a factor of two. On a day when AMKR rises 2 percent, AMKL aims to rise 4 percent; on a day AMKR falls 3 percent, AMKL aims to fall 6 percent. This leverage can be attractive to traders betting strongly on AMKR’s near-term direction, but it comes with a cost that most investors misunderstand: the decay that happens in volatile, sideways markets.
How daily reset leverage works — and costs you money
AMKL resets its leverage target to 2X at the close of every trading day. That reset is necessary because leverage compounds: if the underlying stock rises on day one and falls by the same percentage on day two (a common pattern in volatile stocks), a leveraged fund will underperform the underlying on the round trip. The daily reset tries to limit that erosion, but it cannot eliminate it.
Here is the mechanics: AMKL holds a portfolio of AMKR shares and derivatives (typically swap contracts or synthetic exposure) that collectively aim to deliver 2X the daily percentage return. After the market closes, the fund rebalances to reset the leverage ratio to exactly 2X the value of its net asset value. That rebalancing works fine when the market moves in one direction. But when AMKR is volatile — swinging 4 percent one day and falling 3 percent the next — the drag compounds. A 4 percent rise followed by a 4 percent fall in the underlying yields a net return of -0.16 percent (because the loss is calculated on the higher base after the gain). For AMKL at 2X daily leverage, that same pattern produces a larger loss: roughly -0.65 percent. The effect is small in isolation but catastrophic over months or years if the underlying is choppy and range-bound.
This decay accelerates when the underlying stock swings violently around a flat average. It hits particularly hard in markets that open gaps — sharp moves at the open that trigger morning volatility, then mean revert slightly during the day.
Who AMKR is and why it is so volatile
Marker Therapeutics is a clinical-stage immunotherapy company focused on chimeric antigen receptor T cell (CAR-T) therapies for cancer. The company has no approved drugs and no material revenue. Its business is a pipeline of early-to-mid stage programs. That means the stock lives on sentiment, trial readouts, and regulatory milestones — classic biotech behavior. When a phase 2 trial shows promise, AMKR can spike 20 percent in a single day. When a competitor announces stronger data, it can crater. This volatility is oxygen to AMKL’s decay mechanism.
Clinical-stage biotech stocks are among the most volatile in the market. They are binary: either the science works or it does not, and the market reprices the odds constantly as new data arrives. For a single-stock, 2X leveraged fund, that makes AMKR a difficult underlying — it is exactly the environment where daily reset leverage bleeds money fastest.
The expense ratio and trading mechanics
AMKL’s expense ratio is relatively high compared to broad market ETFs, reflecting the cost of maintaining leveraged synthetic exposure. The fund trades on exchange like a normal ETF, and because it tracks a single volatile stock, its trading volume can be modest on quiet days, which may widen the bid-ask spread and make entry and exit more expensive for retail traders.
The fund is liquid enough for active traders to use, but the combination of leverage cost, daily reset decay, and trading spreads means that holding AMKL is expensive. A trader betting on a sharp near-term move in AMKR might use it tactically for a few days or weeks. A buy-and-hold investor holding it for months or years will almost certainly underperform the underlying stock, and may underperform even after accounting for the 2X leverage.
Real risks and who this is for
The real risk is not just downside amplification — though a 10 percent drop in AMKR means a 20 percent drop in AMKL on the day — but the decay in any market where the underlying is volatile and directionless. A stock that swings wildly but finishes the month flat will have gutted a 2X leveraged fund’s value.
AMKL is designed for active traders with a specific, time-bound bullish thesis on Marker Therapeutics — a planned CAR-T data readout, a regulatory event, or a near-term catalyst. It is not a vehicle for a long-term investor in the company’s science. Anyone holding AMKL for more than a few weeks should model the drag and be prepared to see it compound away value, especially if AMKR enters a period of elevated volatility.
How to research AMKL and AMKR
The prospectus for AMKL is the essential reference for understanding the fund’s mechanics, fees, and risks. The AMKR ticker itself — its clinical pipeline, trial timelines, and regulatory path — is the real driver of the fund’s returns, so anyone considering AMKL must understand Marker Therapeutics first. SEC filings, clinical trial databases (clinicaltrials.gov), and company press releases on pipeline milestones are the places to start. Financial data providers like Yahoo Finance, Morningstar, and ETF tracking websites will show AMKL’s realized returns against AMKR’s, which is the most honest test of whether the fund is working as advertised or whether decay is eroding value.